<code id='B211DDF73C'></code><style id='B211DDF73C'></style>
    • <acronym id='B211DDF73C'></acronym>
      <center id='B211DDF73C'><center id='B211DDF73C'><tfoot id='B211DDF73C'></tfoot></center><abbr id='B211DDF73C'><dir id='B211DDF73C'><tfoot id='B211DDF73C'></tfoot><noframes id='B211DDF73C'>

    • <optgroup id='B211DDF73C'><strike id='B211DDF73C'><sup id='B211DDF73C'></sup></strike><code id='B211DDF73C'></code></optgroup>
        1. <b id='B211DDF73C'><label id='B211DDF73C'><select id='B211DDF73C'><dt id='B211DDF73C'><span id='B211DDF73C'></span></dt></select></label></b><u id='B211DDF73C'></u>
          <i id='B211DDF73C'><strike id='B211DDF73C'><tt id='B211DDF73C'><pre id='B211DDF73C'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:6
          President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT
          President Biden MANDEL NGAN/AFP via Getty Images

          WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

          The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

          advertisement

          “We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Pharmacists can make shortage drugs, but at what cost?
          Pharmacists can make shortage drugs, but at what cost?

          AdobePharmacistsincreasinglyarebeingaskedtomakedrugsinbulkforhospitalsthatareinshortsupply,andthey’r

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Baltimore teen accused of firing into crowd during block party mass shooting

          CAPTIONCORRECTION:CORRECTSDATE:FILE-AchairremainsuprightintheareaofamassshootingincidentintheSouther